SANES

10.692

+1.95%↑

BBVA

19.865

+2.56%↑

BNP

92.21

+2.54%↑

CABK

11.67

+1.97%↑

INGA

27.035

+2.21%↑

SANES

10.692

+1.95%↑

BBVA

19.865

+2.56%↑

BNP

92.21

+2.54%↑

CABK

11.67

+1.97%↑

INGA

27.035

+2.21%↑

SANES

10.692

+1.95%↑

BBVA

19.865

+2.56%↑

BNP

92.21

+2.54%↑

CABK

11.67

+1.97%↑

INGA

27.035

+2.21%↑

SANES

10.692

+1.95%↑

BBVA

19.865

+2.56%↑

BNP

92.21

+2.54%↑

CABK

11.67

+1.97%↑

INGA

27.035

+2.21%↑

SANES

10.692

+1.95%↑

BBVA

19.865

+2.56%↑

BNP

92.21

+2.54%↑

CABK

11.67

+1.97%↑

INGA

27.035

+2.21%↑

Home・Lista de Ações・Bayer AG

Bayer AG

Abrir

SetorFinanças

38.61 0.44

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

38.39

Máximo

38.78

Indicadores-chave
By Trading Economics
Rendimento	6.5B 2.8B
Vendas	2B 13B
EPS	2.812
Rendimento de Dividendos	0.29
Margem de lucro	20.612
Funcionários	87,757
EBITDA	2.3B 4.4B

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+25.11% upside

Dividendos
By Dow Jones
Rendimento de Dividendos Médio do Setor	0.29% 4.64%
Próximos Ganhos	4 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	737M 37B
Abertura anterior	38.17
Fecho anterior	38.61

Sentimento de Notícias

By Acuity

34%

66%

91 / 438 Ranking em Finance

Bayer AG Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

12 de mai. de 2026, 11:24 UTC

Ganhos

Grandes Movimentos do Mercado

Bayer Shares Climb After Earnings Beat Expectations

12 de mai. de 2026, 06:10 UTC

Ganhos

Bayer Net Profit Surges Driven by Growth in Agricultural Division

6 de mai. de 2026, 10:51 UTC

Aquisições, Fusões, Aquisições de Empresas

Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion -- Update

6 de mai. de 2026, 07:01 UTC

Aquisições, Fusões, Aquisições de Empresas

Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion

12 de mai. de 2026, 12:05 UTC

Ações em Alta

Stocks to Watch: GameStop, Venture Global, Wendy's, Hims & Hers -- WSJ

12 de mai. de 2026, 10:51 UTC

Ações em Alta

Stocks to Watch: GameStop, Venture Global, Hims & Hers, GoPro -- WSJ

12 de mai. de 2026, 09:08 UTC

Ações em Alta

Stocks to Watch: Venture Global, Hims & Hers, GoPro -- WSJ

12 de mai. de 2026, 05:38 UTC

Ganhos

Bayer Backs 2026 Outlook Adjusted for Currency

12 de mai. de 2026, 05:36 UTC

Ganhos

Bayer 1Q Consumer Health Sales Grew 5.3%, Adjusted for Currency, Portfolio Changes

12 de mai. de 2026, 05:36 UTC

Ganhos

Bayer 1Q Pharma Sales Fell 0.5%, Adjusted for Currency, Portfolio Changes

12 de mai. de 2026, 05:36 UTC

Ganhos

Bayer 1Q Crop Science Sales Grew 6.8%, Adjusted for Currency, Portfolio Changes

12 de mai. de 2026, 05:35 UTC

Ganhos

Bayer 1Q Adj EPS EUR2.71

12 de mai. de 2026, 05:34 UTC

Ganhos

Analysts Saw Bayer 1Q Net Profit From Continuing Operations at EUR1.60B

12 de mai. de 2026, 05:34 UTC

Ganhos

Analysts Saw Bayer 1Q Ebitda Before Special Items at EUR3.93B

12 de mai. de 2026, 05:34 UTC

Ganhos

Analysts Saw Bayer 1Q Sales at EUR13.42B

12 de mai. de 2026, 05:34 UTC

Ganhos

Bayer 1Q Sales Grew 4.1% When Adjusted for Currency, Portfolio Changes

12 de mai. de 2026, 05:33 UTC

Ganhos

Bayer 1Q EBIT EUR3.53B

12 de mai. de 2026, 05:32 UTC

Ganhos

Bayer 1Q Ebitda Before Special Items EUR4.45B

12 de mai. de 2026, 05:32 UTC

Ganhos

Bayer 1Q Net Pft EUR2.76B

12 de mai. de 2026, 05:31 UTC

Ganhos

Bayer 1Q Sales EUR13.405B

12 de mai. de 2026, 05:31 UTC

Ganhos

Bayer Backs 2026 View

6 de mai. de 2026, 06:34 UTC

Aquisições, Fusões, Aquisições de Empresas

Bayer: Perfuse's Lead Program Is Treatment for Glaucoma and Diabetic Retinopathy

6 de mai. de 2026, 06:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Bayer: Acquisition Aims to Complement Ophthalmology Pipeline

6 de mai. de 2026, 06:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Bayer: Additional Payments Subject to Development, Regulatory, and Commercial Milestones

6 de mai. de 2026, 06:32 UTC

Aquisições, Fusões, Aquisições de Empresas

Bayer to Pay $300M Upfront

6 de mai. de 2026, 06:32 UTC

Aquisições, Fusões, Aquisições de Empresas

Bayer to Buy Perfuse Therapeutics for Up to $2.45B

6 de mai. de 2026, 06:31 UTC

Aquisições, Fusões, Aquisições de Empresas

Bayer to Buy Perfuse Therapeutics

6 de mai. de 2026, 06:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Bayer To Acquire Perfuse Therapeutics To Complement Ophthalmology Pipeline >BAYN.XE

8 de abr. de 2026, 14:41 UTC

Ganhos

Buy Johnson & Johnson Stock Ahead of Earnings, Analyst Says. The Gains Can Continue. -- Barrons.com

1 de abr. de 2026, 14:24 UTC

Conversa de Mercado

Bayer Pharma Head Touts Healthiest Pipeline in Company's History -- Market Talk

Comparação entre Pares

Variação de preço

Bayer AG Previsão

Preço-alvo

By TipRanks

25.11% parte superior

Previsão para 12 meses

Média 48.18 EUR 25.11%

Máximo 56 EUR

Mínimo 25 EUR

Com base em 12 analistas de Wall Street que oferecem metas de preço de 12 meses para Bayer AG - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

12 ratings

Comprar

Manter

Vender

Com base em 12 analistas que deram avaliações de ações para Bayer AG - Dist nos últimos 3 meses.

Sentimento

By Acuity

91 / 438 Ranking em Finanças

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.